Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493587 | 0.90 | CHEK1 (0.31) | HTR2CHTR2AHTR2BCHEK1IKBKE | |
| SCHEMBL6806064 | 0.88 | IKBKE (0.32) | CHEK1IKBKETBK1 | |
| SCHEMBL6503481 | 0.84 | CCR3 (0.31) | HTR2CLRRK2 | |
| SCHEMBL6501374 | 0.84 | PIK3CA (0.36) | HTR2CHTR2AHTR2BCHEK1IKBKE | |
| SCHEMBL6498252 | 0.83 | HTR2C (0.38) | HTR2CHTR2AHTR2BKCNH2LRRK2 | |
| SCHEMBL6491978 | 0.82 | HTR2C (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL6493927 | 0.82 | HTR2C (0.32) | HTR2CHTR2AHTR2B | |
| SCHEMBL6491690 | 0.81 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL6490191 | 0.81 | HTR2C (0.36) | HTR2CHTR2AHTR2BLRRK2CHRNB2 | |
| SCHEMBL6499854 | 0.79 | CHEK1 (0.37) | HTR2CHTR2AHTR2BCHEK1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.